All Publications

• Risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs: Impact of additional confounding control for variables collected from self-reported dataAbstract

  WHAT IS KNOWN AND OBJECTIVE: Important risk factors and over-the-counter (OTC) dispensing of non-steroidal anti-inflammatory drugs (NSAIDs) are often not routinely recorded in electronic health records. This study aimed to assess the impact of patint’s reports on these factors on the risk of acute myocardial infarction (AMI) for NSAID use

  Bakhriansyah M, Souverein PC, de Boer A, Klungel OH. J Clin Pharm Ther. 2019 Apr 7; 44 623-631.

• Effects of European Society of Cardiology guidelines on medication profiles after hospitalization for heart failure in 22,476 Dutch patients: from 2001 until 2015Abstract

  Prescriber adherence to guideline-recommended medication in patients with heart failure (HF) in clinical practice is suboptimal. We analyzed how evolving guideline recommendations influenced medication profiles after a first HF hospitalization. Wextracted medication profiles from the Dutch PHARMO Database Network for 22,476 patients with a diagnosis of HF at hospital discharge between 2001 and 2015

  Kruik-Kolloffel WJ, Linssen GCM, Kruik HJ, Movig KLL, Heintjes EM, van der Palen J. Heart Fail Rev. 2019 Mar 8; 24 499-510.

• All-cause mortality with current and past use of antidepressants or benzodiazepines after major osteoporotic and hip fractureAbstract

  In the first year, after an osteoporotic fracture of a hip, forearm, upper arm, or spine, the dispensing rates of antidepressants and benzodiazepines increased significantly. After those fractures, recent and past use of antidepressants and benzodizepines was associated with increased all-cause mortality; current use was not associated with mortality risk

  deBruin IJA, Klop C, Wyers CE, Overbeek JA, Geusens Ppmm, van den Bergh JPW, Driessen JHM, deVries F. Osteoporos Int. 2019 Feb 8; 30 573-581.

• Real-world insights into risk of developing cardiovascular disease following GnRH agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databasesAbstract

  One of the more recently investigated adverse long-term side effects of gonadotropin-releasing hormone (GnRH) agonists for prostate cancer (PCa) is cardiovascular disease (CVD). Studies suggest lower risk of CVD following GnRH antagonists (degareli) than GnRH agonists. This protocol describes precise codes used to extract variables from five European databases for a study that compares risk of CVD following GnRH agonists and antagonists for PCa

  George G, Scailteux LM, Garmo H, Balusson F, Cardwell C, DeCoster G, DeSchutter H, Kuiper JG, McMenamin U, Verbeeck J, VanHemelrijck M. Fundam Clin Pharmacol. 2019 Feb 18; 33 479-499.

• Type 2 Diabetes, but Not Insulin (Analog) Treatment, Is Associated With More Advanced Stages of Breast Cancer: A National Linkage of Cancer and Pharmacy RegistriesAbstract

  OBJECTIVE: To investigate whether women with type 2 diabetes (T2D) develop a more advanced stage of breast cancer and whether treatment with insulin (analogs) is associated with specific breast cancer characteristics. RESEARCH DESIGN AND METHODS: Fr this nested case-control study, women with breast cancer diagnosed in 2002-2014 were selected from the linked Netherlands Cancer Registry-PHARMO Database Network (N = 33,377)

  Overbeek JA, van Herk-Sukel MPP, Vissers PAJ, van der Heijden Aawa, Bronsveld HK, Herings RMC, Schmidt MK, Nijpels G. Diabetes Care. 2019 Jan 24; 42 434-442.

• Nierfunctie en ernstige bloedingen bij patienten behandeld met cumarinesAbstract

  BACKGROUND: Although anticoagulation therapy is closely monitored in the Netherlands, coumarin-induced serious bleeding events are still observed. Current literature suggests that renal impairment may contribute to this. OBJECTIVE: To explore the asociation between renal function and bleeding events during coumarin treatment

  Houben E, Smits E, Overbeek JA, Penning-van Beest FJA, Herings RMC, van Herk-Sukel MPP, Teichert M, de Smet Pagm. Pharmaceutisch Weekblad. 2019 154 19-28.

• Prevalence of Drug Prescriptions and Potential Safety in Patients with Cirrhosis: A Retrospective Real-World StudyAbstract

  Weersink RianneA, Taxis Katja, Drenth JoostPH, Houben Eline, Metselaar HeroldJ, Borgsteede Sander D. Drug Safety. 2019 42 539-546.

• Brand and generic use of inhalation medication and frequency of switching in children and adults: A population-based cohort studyAbstract

  BACKGROUND: The expiration of patents of brand inhalation medications and the ongoing pressure on healthcare budgets resulted in a growing market for generics. AIM: To study the use of brand and generic inhalation medication and the frequency of swtching between brand and generic and between devices

  Engelkes M, van Blijder veen JC, Overbeek JA, Kuiper J, Herings RCM, Sturkenboom Mcjm, deJongste JC, Verhamme KMC, Janssens HM. J Asthma. 2018 Nov 29; 55 1086-1094.

• Increased risk of morbidities and health-care utilisation in children born following preterm labour compared with full-term labour: A population-based studyAbstract

  AIM: Recent evidence is emerging indicating long-term effects in infants born after an episode of preterm labour (PTL), even if birth is at term. This population-based study compared long-term rates of outcomes and health-care utilisation (HCU) inhildren born following spontaneous preterm labour, irrespective of gestational age at delivery or of an uncomplicated pregnancy (SPTLu), with children born following full-term labour (FTL), overall stratified by comorbidity status and assessed using a composite morbidity measure (CM)

  Houben E, Smits E, Pimenta JM, Black LK, Bezemer ID, Penning-van Beest FJ. J Paediatr Child Health. 2018 Oct 4; 55 446-453.

• Changes in glucose-lowering drug use before and after cancer diagnosis in patients with diabetesAbstract

  AIM: This study explores the changes in glucose-lowering drug (GLD) use before and after cancer diagnosis among patients with diabetes. METHODS: New GLD users (1998-2011) living in the Dutch ECR-PHARMO catchment area were selected from the PHARMO Dtabase Network (n=52,228). Those with a primary cancer diagnosis were considered cases (n=3281) and matched with eligible controls (n=12,891) without cancer during follow-up

  Zander s MMJ, Haak HR, van Herk-Sukel MPP, Herings RMC, van dePoll-Franse LV, Johnson JA. Diabetes Metab. 2018 Oct 21; 44 22 - 29.